Logo for Annexin Pharmaceuticals

Annexin Pharmaceuticals Investor Relations Material

Latest events

Logo for Annexin Pharmaceuticals

Q3 2023

18 Oct, 2023
Logo for Annexin Pharmaceuticals

Q2 2023

3 Aug, 2023
Access the full event backlog
Slides, Transcripts, and Reports from over 8,000 public companies
Annexin Pharmaceuticals AB (publ) is a Swedish biotechnology company that develops drug candidates for the treatment of various cardiovascular diseases. The company develops ANXV, human recombinant protein that protects and repairs blood vessels and counters inflammation. It offers Annexin A5, which is the only drug approved in Canada with this mechanism of action. The company was founded in 2014 and is based in Stockholm, Sweden.